Buchumschlag

Assessing safety and efficacy in subpopulations in Alzheimer's disease clinical trials: contextualizing representativeness

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Guogen Shan, Jeffrey Cummings
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alzheimer's & Dementia: Translational Research & Clinical Interventions
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trials
von: Jeffrey Cummings
Veröffentlicht: (2025)

Biomarkers in Alzheimer's disease clinical trials: 2025
von: Amanda M. Leisgang Osse, et al.
Veröffentlicht: (2026)

Assessing clinical meaningfulness in clinical trials for Alzheimer's disease: A U.S. regulatory perspective
von: Teresa Buracchio, et al.
Veröffentlicht: (2025)

Machine learning–enhanced screening funnel for clinical trials in Alzheimer's disease
von: Scott Gladstein, et al.
Veröffentlicht: (2025)

Alzheimer's disease drug development pipeline: 2026
von: Jeffrey L. Cummings, et al.
Veröffentlicht: (2026)

Alzheimer's disease drug development pipeline: 2025
von: Jeffrey L. Cummings, et al.
Veröffentlicht: (2025)

Critical evaluation of real‐world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation
von: Reina Tonegawa‐Kuji, et al.
Veröffentlicht: (2025)

Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
von: Luke E. Stoeckel, et al.
Veröffentlicht: (2025)

Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease
von: Philip Scheltens, et al.
Veröffentlicht: (2026)

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting
von: Ronald C. Petersen, et al.
Veröffentlicht: (2025)

Implications of practice effects for the design of Alzheimer clinical trials
von: Jasmin A. Duehring, et al.
Veröffentlicht: (2025)

Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
von: Xiaojuan Li, et al.
Veröffentlicht: (2025)

Recruitment of mid‐life adults to a randomized clinical trial: The multicultural healthy diet study to reduce cognitive decline and Alzheimer's disease risk
von: Mindy J. Katz, et al.
Veröffentlicht: (2025)

Designing and implementing the IDEAL Study: A randomized clinical trial of APOE genotype disclosure for late‐onset Alzheimer's disease in an urban Latino population
von: John B. Wetmore, et al.
Veröffentlicht: (2024)

Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug
von: Robyn Moxon, et al.
Veröffentlicht: (2025)

Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
von: Valentina Di Caro, et al.
Veröffentlicht: (2025)

Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof‐of‐principle study and call to action
von: Mark A. Dubbelman, et al.
Veröffentlicht: (2024)

Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease
von: Garrett B. Duncan, et al.
Veröffentlicht: (2025)

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
von: Ronald C. Petersen, et al.
Veröffentlicht: (2025)

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
von: Clifford R. Jack, et al.
Veröffentlicht: (2024)

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients
von: Dawn C. Matthews, et al.
Veröffentlicht: (2024)

Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation
von: Maansi Barnwal, et al.
Veröffentlicht: (2026)

Single‐subject proteomic signatures in Alzheimer's disease reflect clinical phenotypes and distinguish asymptomatic from symptomatic cases
von: Avijit Podder, et al.
Veröffentlicht: (2026)

Blood‐based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost‐effectiveness in Alzheimer's disease prevention studies
von: Kenichiro Sato, et al.
Veröffentlicht: (2025)

Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease
von: Steven E. Arnold, et al.
Veröffentlicht: (2024)

Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease
von: Tuyet Thao Nguyen, et al.
Veröffentlicht: (2026)

Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline
von: Yuan Shang, et al.
Veröffentlicht: (2025)

Impact of study partner replacement in a mild cognitive impairment clinical trial
von: Lucy A. Dolmadjian, et al.
Veröffentlicht: (2025)

Why testing and diagnosis for Alzheimer's disease are mission critical
von: Brent W. Beasley
Veröffentlicht: (2025)

Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease
von: Garrett R. Mullins, et al.
Veröffentlicht: (2025)

Genetic associations with psychosis and affective disturbance in Alzheimer's disease
von: Inga Margret Antonsdottir, et al.
Veröffentlicht: (2024)

Awareness and cognitive rehabilitation in Alzheimer's disease and frontotemporal dementia
von: Eric Salmon, et al.
Veröffentlicht: (2024)

Alzheimer's disease drug development in an evolving therapeutic landscape
von: Stacie Weninger, et al.
Veröffentlicht: (2024)

APOE ‐associated disease risk and sex‐specific effects in Egyptian Alzheimer's disease: an exploratory study
von: Mai Othman, et al.
Veröffentlicht: (2026)

Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease
von: Ralph Kern, et al.
Veröffentlicht: (2025)

Sex differences and the role of estrogens in the immunological underpinnings of Alzheimer's disease
von: Brittani R. Price, et al.
Veröffentlicht: (2025)

Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment
von: Suzanne E. Schindler, et al.
Veröffentlicht: (2026)

A service‐oriented approach to clinical trial recruitment for dementia and brain health: Methods and case examples of MyAlliance for Brain Health
von: Eric D. Vidoni, et al.
Veröffentlicht: (2024)

New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop
von: Maria A. Telpoukhovskaia, et al.
Veröffentlicht: (2024)

Uncovering barriers to early diagnosis of Alzheimer's disease: a European perspective
von: David A. Pérez‐Martínez, et al.
Veröffentlicht: (2025)